A pivotal study of Ad-RTS-hIL-12 + veledimex for recurrent glioblastoma multiforme (GBM)
Phase of Trial: Phase III
Latest Information Update: 12 Oct 2017
At a glance
- Drugs INXN 2001 (Primary) ; Veledimex (Primary)
- Indications Glioblastoma
- Focus Registrational; Therapeutic Use
- Sponsors ZIOPHARM Oncology
- 12 Oct 2017 According to a ZIOPHARM Oncology media release, this trial is expected to begin by the end of 2017.
- 20 Feb 2017 New trial record
- 16 Feb 2017 According to a ZIOPHARM Oncology media release, the company plans to initiate this study in 2017.